These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 28079291)
1. Prognostic Value of PD-L1 in Breast Cancer: A Meta-Analysis. Wang C; Zhu H; Zhou Y; Mao F; Lin Y; Pan B; Zhang X; Xu Q; Huang X; Sun Q Breast J; 2017 Jul; 23(4):436-443. PubMed ID: 28079291 [TBL] [Abstract][Full Text] [Related]
2. Prognostic Role of Programmed Death Ligand-1 Expression in Breast Cancer: A Systematic Review and Meta-Analysis. Li X; Li M; Lian Z; Zhu H; Kong L; Wang P; Yu J Target Oncol; 2016 Dec; 11(6):753-761. PubMed ID: 27422273 [TBL] [Abstract][Full Text] [Related]
3. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients. Tsang JY; Au WL; Lo KY; Ni YB; Hlaing T; Hu J; Chan SK; Chan KF; Cheung SY; Tse GM Breast Cancer Res Treat; 2017 Feb; 162(1):19-30. PubMed ID: 28058578 [TBL] [Abstract][Full Text] [Related]
4. Clinicopathological and prognostic significance of programmed death ligand-1 expression in breast cancer: a meta-analysis. Kim HM; Lee J; Koo JS BMC Cancer; 2017 Oct; 17(1):690. PubMed ID: 29041905 [TBL] [Abstract][Full Text] [Related]
5. Expression of PD-L1 and prognosis in breast cancer: a meta-analysis. Zhang M; Sun H; Zhao S; Wang Y; Pu H; Wang Y; Zhang Q Oncotarget; 2017 May; 8(19):31347-31354. PubMed ID: 28430626 [TBL] [Abstract][Full Text] [Related]
6. Prognostic value of PD-L1 in esophageal squamous cell carcinoma: a meta-analysis. Guo W; Wang P; Li N; Shao F; Zhang H; Yang Z; Li R; Gao Y; He J Oncotarget; 2018 Mar; 9(17):13920-13933. PubMed ID: 29568405 [TBL] [Abstract][Full Text] [Related]
7. [PD-L1 expression and PD-1/PD-L1 inhibitors in breast cancer]. Monneur A; Gonçalves A; Bertucci F Bull Cancer; 2018 Mar; 105(3):263-274. PubMed ID: 29455872 [TBL] [Abstract][Full Text] [Related]
8. Prognostic and Clinicopathological Value of Programmed Death Ligand-1 in Breast Cancer: A Meta-Analysis. Guo Y; Yu P; Liu Z; Maimaiti Y; Wang S; Yin X; Liu C; Huang T PLoS One; 2016; 11(5):e0156323. PubMed ID: 27227453 [TBL] [Abstract][Full Text] [Related]
9. Role of programmed cell death ligand-1 expression on prognostic and overall survival of breast cancer: A systematic review and meta-analysis. Li S; Chen L; Jiang J Medicine (Baltimore); 2019 Apr; 98(16):e15201. PubMed ID: 31008945 [TBL] [Abstract][Full Text] [Related]
10. Prognostic and clinicopathological significance of PD-L1 in patients with renal cell carcinoma: a meta-analysis based on 1863 individuals. Wang Z; Peng S; Xie H; Guo L; Cai Q; Shang Z; Jiang N; Niu Y Clin Exp Med; 2018 May; 18(2):165-175. PubMed ID: 29362922 [TBL] [Abstract][Full Text] [Related]
11. Prognostic and clinicopathological value of PD-L1 in colorectal cancer: a systematic review and meta-analysis. Yang L; Xue R; Pan C Onco Targets Ther; 2019; 12():3671-3682. PubMed ID: 31190869 [No Abstract] [Full Text] [Related]
12. Prognostic value of programmed cell death ligand-1 expression in breast cancer: A meta-analysis. Zhang Y; Tian J; Qu C; Tang Z; Wang Y; Li K; Yang Y; Liu S Medicine (Baltimore); 2020 Dec; 99(49):e23359. PubMed ID: 33285715 [TBL] [Abstract][Full Text] [Related]
13. Prognostic and clinicopathological value of PD-L1 expression in primary breast cancer: a meta-analysis. Huang W; Ran R; Shao B; Li H Breast Cancer Res Treat; 2019 Nov; 178(1):17-33. PubMed ID: 31359214 [TBL] [Abstract][Full Text] [Related]
14. Prognostic value of PD-L1 expression in tumor infiltrating immune cells in cancers: A meta-analysis. Zhao T; Li C; Wu Y; Li B; Zhang B PLoS One; 2017; 12(4):e0176822. PubMed ID: 28453554 [TBL] [Abstract][Full Text] [Related]
15. Prognostic Value of Programmed Cell Death Ligand-1 Expression in Nasopharyngeal Carcinoma: A Meta-Analysis of 1,315 Patients. Liu X; Shan C; Song Y; Du J Front Oncol; 2019; 9():1111. PubMed ID: 31709181 [No Abstract] [Full Text] [Related]
16. Prognostic significance of programmed cell death ligand 1 expression in patients with ovarian carcinoma: A systematic review and meta-analysis. Huang LJ; Deng XF; Chang F; Wu XL; Wu Y; Diao QZ Medicine (Baltimore); 2018 Oct; 97(43):e12858. PubMed ID: 30412078 [TBL] [Abstract][Full Text] [Related]
17. Programmed death-ligand 1 gene expression is a prognostic marker in early breast cancer and provides additional prognostic value to 21-gene and 70-gene signatures in estrogen receptor-positive disease. Zerdes I; Sifakis EG; Matikas A; Chrétien S; Tobin NP; Hartman J; Rassidakis GZ; Bergh J; Foukakis T Mol Oncol; 2020 May; 14(5):951-963. PubMed ID: 32115850 [TBL] [Abstract][Full Text] [Related]
18. Predictive values of PD‑L1 expression for survival outcomes in patients with cervical cancer: a systematic review and meta-analysis. Hu T; Wan X; Wu H; Cheng X; Xu S Ginekol Pol; 2022; 93(10):767-774. PubMed ID: 35984342 [TBL] [Abstract][Full Text] [Related]
19. Increased programmed death ligand-1 expression predicts poor prognosis in hepatocellular carcinoma patients. Gu X; Gao XS; Xiong W; Guo W; Han L; Bai Y; Peng C; Cui M; Xie M Onco Targets Ther; 2016; 9():4805-13. PubMed ID: 27536144 [TBL] [Abstract][Full Text] [Related]
20. Prognostic Implications of PD-L1 Expression in Breast Cancer: Systematic Review and Meta-analysis of Immunohistochemistry and Pooled Analysis of Transcriptomic Data. Matikas A; Zerdes I; Lövrot J; Richard F; Sotiriou C; Bergh J; Valachis A; Foukakis T Clin Cancer Res; 2019 Sep; 25(18):5717-5726. PubMed ID: 31227501 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]